Kymab Limited

Richard Charles Alfred Sainson

Jamie Iain Campbell

Matthew John McCourt

Stephen John Arkinstall

E-Chiang Lee

Ian Kirby

Miha Kosmac

Volker Germaschewski

Mohammed Hanif Ali

Stephen D Gillies

Cassandra Van Krinks

Nikole Sandy

Thomas Gallagher

Nahida Parveen

Mihriban Tuna

Francisca Wollerton Van Horck

Mustapha Faroudi

Cecilia Deantonio

Joana De Abreu Carvalho

Ryan Fiehler

Frederick Akele

Fadi Badr

Gwenoline Borhis

Rachael Jane Kimber

Robert Rowlands

Jacob Galson

Aksana Labokha

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.

Antibodies to ICOS

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Anti-ICOS antibodies

Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.

Bispecific antibody for ICOS and PD-L1

The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo

Growing community of inventors

Cambridge, United Kingdom

Richard Charles Alfred Sainson